Jinling Pharmaceutical Company Limited (SHE:000919)

SHE:000919 Revenue

Jinling Pharmaceutical Company had revenue of 815.76M CNY in the quarter ending June 30, 2026, with 3.12% growth. This brings the company's total for the last twelve months to 3.18B, up 0.40% year-over-year. In the year 2025, Jinling Pharmaceutical Company had annual revenue of 3.20B, down -2.56%. That makes Jinling Pharmaceutical Company the 11,512th largest company in the world by revenue and 1,934th in China.

• Revenue (ttm): 3.18B
• Revenue Growth: +0.40%
• P/S Ratio: 1.22
• Revenue / Employee: 556.45K
• Employees: 5,716
• Market Cap: 3.87B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medical Services 1.65B 51.6%
• Medicine Production and Sales 1.49B 46.7%
• Others 53.65M 1.7%

By Geography

Chart

• East China 2.91B 91.1%
• Central and Southwest China 151.22M 4.7%
• North China 66.27M 2.1%
• Northwest China 45.63M 1.4%
• Northeast China 13.51M 0.4%
• Overseas 5.44M 0.2%
• Xinjiang Region 2.96M 0.1%

Fiscal year ended Dec 31, 2025 See the full SHE:000919 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.20B	-84.13M	-2.56%
Dec 31, 2024	3.28B	87.45M	2.74%
Dec 31, 2023	3.19B	523.03M	19.58%
Jan 1, 2023	2.67B	-137.79M	-4.91%
Jan 1, 2022	2.81B	305.02M	12.18%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error